Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.79 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | FLT3 | P36888 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | JAK1 | P23458 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31163120 | 0.90 | BRD4 (0.75) | BRD4JAK2FLT3 | |
| SCHEMBL31163118 | 0.89 | BRD4 (0.67) | BRD4JAK2FLT3JAK1 | |
| SCHEMBL17526180 | 0.88 | BRD4 (1.00) | BRD4JAK2FLT3 | |
| SCHEMBL28980990 | 0.87 | SRC (0.69) | BRD4JAK2FLT3 | |
| SCHEMBL17526046 | 0.85 | BRD4 (1.00) | BRD4JAK2FLT3NPC1RAB9A | |
| SCHEMBL31163153 | 0.85 | BRD4 (0.66) | BRD4JAK2FLT3 | |
| SCHEMBL31163086 | 0.85 | BRD4 (0.85) | BRD4JAK2FLT3JAK1 | |
| SCHEMBL31163142 | 0.84 | BRD4 (0.63) | BRD4JAK2FLT3JAK1 | |
| SCHEMBL265060 | 0.83 | BRD4 (0.82) | BRD4JAK2FLT3JAK1 | |
| SCHEMBL31163056 | 0.83 | BRD4 (0.76) | BRD4JAK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024179699-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC. (US) | 2024-09-06 | — | — | WO | disclosed |